Recursion Pharmaceuticals, Inc.
RXRX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | – | $2,111,847 | $2,130,664 | $2,271,603 |
| - Cash | $659,836 | $528,216 | $500,453 | $594,350 |
| + Debt | $61,930 | $88,075 | $92,910 | $108,492 |
| Enterprise Value | – | $1,671,706 | $1,723,121 | $1,785,745 |
| Revenue | $5,175 | $19,103 | $14,745 | $4,511 |
| % Growth | -72.9% | 29.6% | 226.9% | – |
| Gross Profit | -$24,418 | -$1,058 | -$7,084 | -$8,283 |
| % Margin | -471.8% | -5.5% | -48% | -183.6% |
| EBITDA | -$141,207 | -$147,568 | -$182,806 | -$165,343 |
| % Margin | -2,728.6% | -772.5% | -1,239.8% | -3,665.3% |
| Net Income | -$162,253 | -$171,897 | -$202,487 | -$178,906 |
| % Margin | -3,135.3% | -899.8% | -1,373.3% | -3,966% |
| EPS Diluted | -0.36 | -0.41 | -0.5 | -0.53 |
| % Growth | 12.2% | 18% | 5.7% | – |
| Operating Cash Flow | -$117,360 | -$76,418 | -$131,957 | -$115,430 |
| Capital Expenditures | -$243 | -$3,150 | -$1,832 | -$1,648 |
| Free Cash Flow | -$117,603 | -$79,568 | -$133,789 | -$117,078 |